News: Amgen

06.09.2010 | Business Wire: Research and Markets: Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6e510d/manufacturing_of_b) has announced the addition of the "Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in (…)

[Read article]

[Source: Business Wire]

02.09.2010 | Business Wire: ImmunoGen, Inc. Announces Webcast of Presentations at Multiple Investor Conferences in September | Business Wire

WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, today announced that Company management will present at multiple investor conferences this month. The live webcast of each (…)

[Read article]

[Source: Business Wire]

31.08.2010 | Business Wire: Research and Markets: This Biotechnology in Japan Industry Profile Is an Essential Resource for Top-Level Data and Analysis | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/05f568/biotechnology_in_j) has announced the addition of the "Biotechnology in Japan" report to their offering. The Biotechnology in Japan industry profile is an essential resource for (…)

[Read article]

[Source: Business Wire]

31.08.2010 | BioSpace: BioCision, LLC Signs Agreement with SERVA Electrophoresis GmbH for Distribution of CoolTech Products in Europe

MILL VALLEY, Calif. - March 26, 2010 - BioCision LLC today announced that it has signed a European distribution agreement with SERVA Electrophoresis, a global supplier of reagents for scientific research. SERVA Electrophoresis will sell BioCision s entire portfolio of (…)

[Read article]

[Source: BioSpace]

31.08.2010 | BioSpace: BioCision, LLC Lands New Distribution Partner with Biophoretics Deal

MILL VALLEY, Calif. February 11, 2010 - BioCision LLC, the CoolRack ¢ company, announced today that it has entered into a distribution agreement with Biophoretics, a developer and distributor of advanced tools for scientific research. Biophoretics will sell BioCision s entire (…)

[Read article]

[Source: BioSpace]

31.08.2010 | BioSpace: BioCision, LLC Signs Distribution Deal with Capital Biosciences, Inc.

MILL VALLEY, Calif. - BioCision LLC, the CoolRack ¢ company, announced today that is has reached an agreement with Capital Biosciences Inc. for the distribution of BioCision's products, which standardize the handling and processing of temperature-sensitive samples. œCapital (…)

[Read article]

[Source: BioSpace]

30.08.2010 | Business Wire: Maven Semantic: Database of Dermatology Research | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Dermatology research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible - (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: EHSI: MedAnywhere Breakthrough Medical iPhone App Module Proceeds to Final Testing Phase | Business Wire

HOUSTON-(BUSINESS WIRE)-Emerging Healthcare Solutions, Inc. (Pink Sheets:EHSI) disclosed today that their first comprehensive medical iPhone Application module named MedAnywhere HHC has entered the final phase of development. MedAnywhere is an iPhone application that contains (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Research and Markets: This Analysis Examines the Historical and Forecast Performance for Johnson & Johnson in the Ethical Pharmaceutical Sector | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/aabcf1/johnson_johnson) has announced the addition of the "Johnson & Johnson: PharmaVitae Profile" company profile to their offering. Introduction This analysis examines the historical and (…)

[Read article]

[Source: Business Wire]

30.08.2010 | BioSpace: BioCision, LLC and Biohit Partner to Co-Promote Complementary Products

MILL VALLEY, Calif., March 31 /PRNewswire/ - BioCision LLC today announced that it has agreed to a co-promotion program with Biohit Inc. (www.us.biohit.com). Biohit's ErgoTube microcentrifuge tubes will now be branded and sold by both Biohit Inc. and BioCision. In addition, (…)

[Read article]

[Source: BioSpace]

26.08.2010 | ScienceDaily: Common Blood Changes Not Independent Predictor of Adverse Outcomes for Kidney Disease Patients, Study Finds

ScienceDaily (Aug. 26, 2010) Fluctuations in blood composition that often arise from commonly used therapies among kidney disease patients are not an independent predictor of adverse outcomes for European hemodialysis patients, according to a study appearing in an upcoming (…)

[Read article]

[Source: ScienceDaily]

27.08.2010 | Medical News Today: American Lung Association Joins Lung Cancer Clinical Trial Call To Action Campaign

The American Lung Association is encouraging patients with lung cancer to take charge of their diagnosis and learn about clinical trials through the Lung Cancer Clinical Trial Call to Action campaign. This service provides personalized education to quickly identify trial (…)

[Read article]

[Source: Medical News Today]

27.08.2010 | Medical News Today: Common Blood Cell Variations Not An Independent Predictor Of Adverse Outcomes For European Kidney Disease Patients

Fluctuations in blood composition that often arise from commonly used therapies among kidney disease patients are not an independent predictor of adverse outcomes for European hemodialysis patients, according to a study appearing in an upcoming issue of the Journal of the (…)

[Read article]

[Source: Medical News Today]

27.08.2010 | Business Wire: Research and Markets: Novel Antibodies and Therapeutic Proteins - Technology Challenges and Future Prospects | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/883f56/novel_antibodies_a) has announced the addition of the "Novel Antibodies and Therapeutic Proteins - Technology Challenges and Future Prospects" report to their offering. Novel (…)

[Read article]

[Source: Business Wire]

25.08.2010 | NCBI PubMed: Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study.

OBJECTIVE.: To evaluate changes in vascular and musculoskeletal involvement in subjects in the Scleroderma Lung Study (SLS), a multicenter, double-blind, randomized, controlled trial comparing placebo treatment to oral cyclophosphamide for 1 year in systemic sclerosis (SSc) (…)

[Read article]

[Source: NCBI PubMed]

25.08.2010 | NCBI PubMed: Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer.

Context: Antiangiogenic therapies have shown potential in the treatment of advanced thyroid cancer, but it is uncertain which patients are most likely to benefit from therapy. Objective: This prespecified exploratory analysis investigated whether baseline levels and/or changes (…)

[Read article]

[Source: NCBI PubMed]

27.08.2010 | BioSpace: Genentech (RHHBY), ImmunoGen, Inc. (IMGN) Receives Refuse to File Letter from FDA for Drug T-DM1, Immunogen Stock Drops 36.35% at 1:49 PM EDT

WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN - News), a biotechnology company that develops antibody-based targeted anticancer products, today announced that Genentech, a member of the Roche Group, today announced its receipt of a Refuse to File (RTF) letter (…)

[Read article]

[Source: BioSpace]

27.08.2010 | Bionity.com: Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of DirectorsRubinfeld expected to assist with FDA approval process for autologous cultured skin substitute, PermaDerm(TM)

27.08.2010 - Regenicin, Inc., a clinical-stage biotechnology company, announced that Dr. Joseph Rubinfeld, one of the four original founders of Amgen, Inc., has agreed to join the company's board of directors. Dr. Rubinfeld will be instrumental to assisting the compan's (…)

[Read article]

[Source: Bionity.com]

26.08.2010 | Marketwire: Swedish Orphan Biovitrum's Kineret has Received Orphan Drug Designation in the USA

STOCKHOLM, SWEDEN-(Marketwire - August 26, 2010) - Swedish Orphan Biovitrum (STO: SOBI) today announced that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to Kineret for the treatment of cryopyrin-associated periodic (…)

[Read article]

[Source: Marketwire]

26.08.2010 | Business Wire: Research and Markets: This Comprehensive Global Biotechnology Industry Profile is an Essential Resource for Top-Level Data and Analysis | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/7e40cd/global_biotechnolo) has announced the addition of the "Global Biotechnology" report to their offering. The Global Biotechnology industry profile is an essential resource for (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Maven Semantic: Genetically Modified Organisms (GMO) Database | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Genetically Modified Organisms research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Maven Semantic: Tissue Banking Research | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Tissue Banking research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Research and Markets: Best Practices in Working with Patient Advocacy Groups: Building Effective Relationships | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/360241/best_practices_in) has announced the addition of the "Best Practices in Working with Patient Advocacy Groups: Building Effective Relationships" report to their offering. Best (…)

[Read article]

[Source: Business Wire]

25.08.2010 | NCBI PubMed: Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys.

Hepcidin is a key regulator responsible for systemic iron homeostasis. A semi-mechanistic PK model for hepcidin and a fully human anti-hepcidin monoclonal antibody (Ab 12B9m) was developed to describe their total (free + bound) serum concentration-time data after single and (…)

[Read article]

[Source: NCBI PubMed]

25.08.2010 | Business Wire: Research and Markets: Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/b5aaab/pharmaceutical_new) has announced the addition of the "Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability 2010" report to their (…)

[Read article]

[Source: Business Wire]

25.08.2010 | Business Wire: Maven Semantic: Biomarker Research Database | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Biomarker research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible - (…)

[Read article]

[Source: Business Wire]

25.08.2010 | Business Wire: Maven Semantic: Database of International Inflammatory Bowel Disease Research | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Inflammatory Bowel Disease research database. , based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be (…)

[Read article]

[Source: Business Wire]

24.08.2010 | Business Wire: Breau Leads Bioanalytical/Analytical Division at MPI Research | Business Wire

MATTAWAN, Mich.-(BUSINESS WIRE)-MPI Research, the largest single-site preclinical contract research organization worldwide, is pleased to announce that Alan P. Breau, PhD, has joined the company as Vice President of its Bioanalytical and Analytical Services (B/AS) division. (…)

[Read article]

[Source: Business Wire]

23.08.2010 | Business Wire: Maven Semantic: The Largest Database of International Osteoporosis Research Professionals | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Osteoporosis research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible (…)

[Read article]

[Source: Business Wire]

19.08.2010 | ScienceDaily: With Muscle-Building Treatment, Mice Live Longer Even as Tumors Grow

ScienceDaily (Aug. 19, 2010) In the vast majority of patients with advanced cancer, their muscles will gradually waste away for reasons that have never been well understood. Now, researchers reporting in the August 20 issue of Cell, have found some new clues and a way to (…)

[Read article]

[Source: ScienceDaily]

21.08.2010 | Medical News Today: Dr Reddy's Launches Darbepoetin Alfa In India Under The Brand Name 'Cresp' World's First Generic Darbepoetin Alfa And The Only One In India

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) announced the launch of Cresp' the first generic darbepoetin alfa in the world, and the only darbepoetin alfa in India. Cresp has been approved in India for the treatment of anemia due to chronic kidney disease and anemia due to (…)

[Read article]

[Source: Medical News Today]

20.08.2010 | NCBI PubMed: Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival.

Muscle wasting and cachexia have long been postulated to be key determinants of cancer-related death, but there has been no direct experimental evidence to substantiate this hypothesis. Here, we show that in several cancer cachexia models, pharmacological blockade of ActRIIB (…)

[Read article]

[Source: NCBI PubMed]

01.09.2010 | NCBI PubMed: Out of the medicine closet: time to talk straight about prescription drug abuse.

Clin Pharmacol Ther. |-| Haller C, James L. |-| Amgen, Inc., South San Francisco, California, USA.

[Read article]

[Source: NCBI PubMed]

01.08.2010 | NCBI PubMed: Identification of a mixed microparticle by combined microspectroscopic techniques: a real forensic case study in the biopharmaceutical industry.

Identification of foreign microparticles in drug products is one of the first steps in evaluating the nature of particle contamination and its consequences for product quality. To characterize various foreign particles, we use spectral database search methods as well as a (…)

[Read article]

[Source: NCBI PubMed]

01.08.2010 | NCBI PubMed: 32nd national medicinal chemistry symposium - medicinal chemistry developments for neurodegeneration, diabetes and cancer.

The 32nd National Medicinal Chemistry Symposium, held in Minneapolis, MN, USA, included topics covering new developments in the field of medicinal chemistry. This conference report highlights selected presentations on Hsp90 inhibitors and Hsp70 inducers, such as KU-32 and (…)

[Read article]

[Source: NCBI PubMed]

19.08.2010 | Business Wire: CORRECTING and REPLACING Amedisys, Inc. Named One of FORTUNE s œ100 Fastest-Growing Companies  | Business Wire

NEW YORK-(BUSINESS WIRE)-In the contact information, Jacqueline Chen Valencia s phone number should be 225-295-9688 (sted 602-790-9612). The troubled economy is on all of our minds these days, but sometimes we forget that even in the long slog we seem to be in, entrepreneurs (…)

[Read article]

[Source: Business Wire]

19.08.2010 | Business Wire: Research and Markets: Market Access in Japan: New Challenges and Opportunities for the Pharmaceutical Industry | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e3c0d9/market_access_in_j) has announced the addition of Decision Resources, Inc.'s new report "Market Access in Japan: New Challenges and Opportunities for the Pharmaceutical Industry" to (…)

[Read article]

[Source: Business Wire]

12.09.2010 | NCBI PubMed: Development of a novel mammalian cell surface antibody display platform.

Antibody display systems have been successfully applied to screen, select and characterize antibody fragments. These systems typically use prokaryotic organisms such as phage and bacteria or lower eukaryotic organisms, such as yeast. These organisms possess either no or (…)

[Read article]

[Source: NCBI PubMed]

18.08.2010 | Business Wire: Research and Markets: Biomarkers: Discovery Techniques and Applications - a Global Market Overview | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/bd425b/biomarkers_discov) has announced the addition of the "Biomarkers: Discovery Techniques and Applications A Global Market Overview" report to their offering. Biomarkers: Discovery (…)

[Read article]

[Source: Business Wire]

18.08.2010 | Business Wire: Emerging Healthcare Solutions Inks Option for Breakthrough Stem Cell Technology | Business Wire

HOUSTON-(BUSINESS WIRE)-Emerging Healthcare Solutions, Inc. (Pink Sheets:EHSI) announced today that the Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. The core technology on which (…)

[Read article]

[Source: Business Wire]

18.08.2010 | Business Wire: ImmunoGen, Inc. Announces Orphan Drug Designation Granted to Lorvotuzumab Mertansine for Treatment of Small-Cell Lung Cancer | Business Wire

WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lorvotuzumab mertansine (…)

[Read article]

[Source: Business Wire]

12.08.2010 | NCBI PubMed: The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine core.

The discovery of a series of novel and orally efficacious type II calcimimetics, developed from the lead compound 1, is described herein. Compound 22 suppressed plasma PTH levels relative to vehicle when dosed orally in a rat pharmacodynamic model. |-| Bioorg Med Chem Lett. |-| (…)

[Read article]

[Source: NCBI PubMed]